|
[1]
|
MOK TS,WU YL,THONGPRASERT S,et al.Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma[J].N Engl J Med,2009,361(10):947. |
|
[2]
|
MOK TS,WU YL,AHN MJ,et al.Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer[J].N Engl J Med,2017,376(7):629. |
|
[3]
|
SOLOMON BJ,MOK T,KIM DW,et al.First-line crizotinib versus chemotherapy in ALK-positive lung cancer[J].N Engl J Med,2014,371(23):2167. |
|
[4]
|
SHAW AT,OU SH,BANG YJ,et al.Crizotinib in ROS1-rearranged non-small-cell lung cancer[J].N Engl J Med,2014,371(21):1963. |
|
[5]
|
PLANCHARD D,SMIT EF,GROEN HJM,et al.Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer:an open-label,phase 2 trial[J].Lancet Oncol,2016,17(7):984. |
|
[6]
|
CARBONE DP,RECK M,PAZ-ARES L,et al.First-line nivolumab in stage IV or recurrent non-small-cell lung cancer[J].N Engl J Med,2017,376(25):2415. |
|
[7]
|
OU SH,KWAK EL,SIWAK-TAPP C.Activity of crizotinib (PF02341066),a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor,in a non-small cell lung cancer patient with de novo MET amplification[J].J Thorac Oncol,2011,6(5):942. |
|
[8]
|
PAIK PK,DRILON A,FAN PD,et al.Response to MET inhibitors in patients with stage IV lung adenocarcinomas harboring MET mutations causing exon 14 skipping[J].Cancer Discov,2015,5(8):842. |
|
[9]
|
DRILON A,REKHTMAN N,ARCILA M,et al.Cabozantinib in patients with advanced RET-rearranged non-small-cell lung cancer:an open-label,single-centre,phase 2,single-arm trial[J].Lancet Oncol,2016,17(12):1653. |
|
[10]
|
LEE SH,LEE JK,AHN MJ,et al.Vandetanib in pretreated patients with advanced non-small cell lung cancer-harboring RET rearrangement:a phase Ⅱ clinical trial[J].Ann Oncol,2017,28(2):292. |
|
[11]
|
DONG ZY,ZHONG WZ,ZHANG XC,et al.Potential Predictive Value of TP53 and KRAS Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma[J].Clin Cancer Res,2017,23(12):3012. |
|
[12]
|
DONG ZY,ZHONG WZ,ZHANG XC,et al.Potential Predictive Value of TP53 and KRAS Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma[J].Clin Cancer Res,2017,23(12):3012. |
|
[13]
|
DOUILLARD JY,OLINER KS,SIENA S,et al.Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer[J].N Engl J Med,2013,369(11):1023. |
|
[14]
|
HONG DS,MORRIS VK,EL OB,et al.Phase IB Study of Vemurafenib in Combination with Irinotecan and Cetuximab in Patients with Metastatic Colorectal Cancer with BRAFV600E Mutation[J].Cancer Discov,2016,6(12):1352. |
|
[15]
|
URAM JN,WANG H,BARTLEEE B,et al.PD-1 blockade in tumors with mismatch-repair deficiency[J].J Clin Oncol,2015,33(18 suppl):LBA100. |
|
[16]
|
PARIKH A,ATREYA C,KORN WM,et al.Prolonged Response to HER2-Directed Therapy in a Patient With HER2-Amplified,Rapidly Progressive Metastatic Colorectal Cancer[J].J Natl Compr Canc Netw,2017,15(1):3. |
|
[17]
|
WANG WL,CONLEY A,REYNOSO D,et al.Mechanisms of resistance to imatinib and sunitinib in gastrointestinal stromal tumor[J].Cancer Chemother Pharmacol,2011,67(1):15. |
|
[18]
|
TRENT JC,WATHEN K,MEHREN MV.A phase Ⅱ study of dasatinib for patients with imatinib-resistant gastrointestinal stromal tumor (GIST)[J].Deutsche Zahnärztliche Zeitschrift,2011,40(8):869. |
|
[19]
|
MATEO J,CARREIRA S,SANDHU S,et al.DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer[J].N Engl J Med,2015,373(18):1697. |
|
[20]
|
CHENG HH,PRITCHARD CC,BOYD T.Biallelic inactivation of BRCA2 in platinum-sensitive metastatic castration-resistant prostate cancer[J].Eur Urol,2016,69(6):992. |
|
[21]
|
MIAO D,MARGOLIS CA,GAO W,et al.Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma[J].Biol Blood Marrow Transplant,2017,8(1):5951. |
|
[22]
|
TEO MY,SEIER K,OSTROVNAYA I,et al.Alterations in DNA Damage Response and Repair Genes as Potential Marker of Clinical Benefit From PD-1/PD-L1 Blockade in Advanced Urothelial Cancers[J].J Clin Oncol,2018,36(17):1685. |
|
[23]
|
ROBSON M,IM SA,SENKUS E,et al.Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation[J].N Engl J Med,2017,377(6):523. |
|
[24]
|
LONG GV,STROYAKOVSKIY D,GOGAS H,et al.Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma:a multicentre,double-blind,phase 3 randomised controlled trial[J].Lancet,2015,386(9992):444. |
|
[25]
|
BROSE MS,CABANILLAS ME,COHEN EE,et al.Vemurafenib in patients with BRAF(V600E)-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine:a non-randomised,multicentre,open-label,phase 2 trial[J].Lancet Oncol,2016,17(9):1272. |
|
[26]
|
HEGI ME,DISERENS AC,GORLIA T,et al.MGMT gene silencing and benefit from temozolomide in glioblastoma[J].N Engl J Med,2005,352(10):997. |
|
[27]
|
BURGER MC,RONELLENFITSCH MW,LORENZ NI,et al.Dabrafenib in patients with recurrent,BRAF V600E mutated malignant glioma and leptomeningeal disease[J].Oncol Rep,2017,38(6):3291. |
|
[28]
|
ROBINSON GW,ORR BA,GAJJAR A.Complete clinical regression of a BRAF V600E-mutant pediatric glioblastoma multiforme after BRAF inhibitor therapy[J].BMC Cancer,2014,14(1):258. |
|
[29]
|
LE DT,DURHAM JN,SMITH KN,et al.Mismatch-repair deficiency predicts response of solid tumors to PD-1 blockade[J].Science,2017,357(6349):409. |
|
[30]
|
HAINSWORTH JD,MERICBERNSTAM F,SWANTON C,et al.Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles:Results From MyPathway,an Open-Label,Phase Ⅱa Multiple Basket Study[J].J Clin Oncol,2018,36(6):536. |
|
[31]
|
DRILON A,LAETSCH TW,KUMMAR S,et al.Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children[J].N Engl J Med,2018,378(8):731. |
点击查看大图
下载:
